Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis

Abstract

Introduction Radiotherapy provides excellent outcome in early stage glottic cancer; however, the optimal radiotherapy dose fractionation remains unknown.

Objective To investigate the outcome of patients with T2N0M0 treated with either hypofractionated (HypoFxn) or conventionally fractionated radical (ConFxn) radiotherapy.

Methods According to our institutional protocol, patients with T2N0M0 glottic cancer can be treated either with ConfFxn or HypoFxn radiotherapy, as per clinician's and patient's choice, following shared decision making discussing the advantages and disadvantages of both modalities. A total of 77 patients with T2N0M0 squamous cell carcinoma of glottis treated with either HypoFxn 55Gy in 20 fractions (n = 19) or ConFxn 63 to 65Gy in 30 fractions (n = 58) were included.

Results With median follow-up of 3.4 years, there was no significant difference in disease-free survival (median: HypoFxn = 65.2 months, and ConFxn = 75.3 months; p = 0.874), local recurrence free survival rates (median: HypoFxn = 78.8 months vs. ConFxn = 81.2 months; p = 0.274), and overall survival (median: HypoFxn = 65.9 months vs. ConFxn = 67.7 months; p = 0.532). Elective neck irradiation was given to 43 patients, all in the ConFxn group, and this was associated with poorer local control (p = 0.027). The use of radiotherapy modality, three-dimensional conformal radiotherapy (3DRT) versus intensity modulated radiotherapy (IMRT), was not a prognostic factor (p = 0.36). In the HypoFxn group, grade III acute dysphagia requiring nasogastric tube was 16%, compared with 25% in the ConFxn group (p = 0.446).

Conclusion HypoFxn radiotherapy provides a comparable treatment outcome with acceptable toxicity. The addition of prophylactic irradiation of the neck lymph nodes has no impact on regional control.

Keywords

T2N0M0 - glottis - larynx - radiotherapy - hypofractionated

• References

• 1 Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62 (01) 10-29
• 2 Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer 2004; 100 (09) 1786-1792
• 3 Dey P, Arnold D, Wight R, MacKenzie K, Kelly C, Wilson J. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database Syst Rev 2002; (02) CD002027
• 4 Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx042. PMID: 28521361
• 5 Lee JW, Lee JE, Park J, Sohn JH, Ahn D. Hypofractionated radiotherapy for early glottic cancer: a retrospective interim analysis of a single institution. Radiat Oncol J 2019; 37 (02) 82-90
• 6 Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M. Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006; 64 (01) 77-82
• 7 Moon SH, Cho KH, Chung EJ. et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol 2014; 110 (01) 98-103
• 8 Kim TG, Ahn YC, Nam HR. et al. Definitive radiation therapy for early glottic cancer: experience of two fractionation schedules. Clin Exp Otorhinolaryngol 2012; 5 (02) 94-100
• 9 Laskar SG, Baijal G, Murthy V. et al. Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution. Clin Oncol (R Coll Radiol) 2012; 24 (10) e180-e186
• 10 Jamshed AHR, Rehman K, Iqbal H. et al. Hypofractionated radiotherapy in the treatment of early glottic cancer. Int J Head Neck Surg 2011; 2: 138-143
• 11 Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM. T1N0 to T2N0 squamous cell carcinoma of the glottic larynx treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2010; 78 (02) 461-466
• 12 Short S, Krawitz H, Macann A. et al. TN/TN glottic carcinoma: a comparison of two fractionation schedules. Australas Radiol 2006; 50 (02) 152-157
• 13 Rosen CA, Lee AS, Osborne J, Zullo T, Murry T. Development and validation of the voice handicap index-10. Laryngoscope 2004; 114 (09) 1549-1556
• 14 Arffa RE, Krishna P, Gartner-Schmidt J, Rosen CA. Normative values for the Voice Handicap Index-10. J Voice 2012; 26 (04) 462-465
• 15 Jones AS, Fish B, Fenton JE, Husband DJ. The treatment of early laryngeal cancers (T1-T2 N0): surgery or irradiation?. Head Neck 2004; 26 (02) 127-135
• 16 Stokes WA, Stumpf PK, Jones BL. et al. Patterns of fractionation for patients with T2N0M0 glottic larynx cancer undergoing definitive radiotherapy in the United States. Oral Oncol 2017; 72: 110-116
• 17 Dixon LM, Douglas CM, Shaukat SI. et al. Conventional fractionation should not be the standard of care for T2 glottic cancer. Radiat Oncol 2017; 12 (01) 178
• 18 Adeel M, Faisal M, Rashid A. et al. Outcomes of definitive radiotherapy for early laryngeal cancer in terms of survival and patterns of failure. J Laryngol Otol 2019; 133 (12) 1087-1091
• 19 Frata P, Cellai E, Magrini SM. et al. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys 2005; 63 (05) 1387-1394
• 20 Sert F, Kaya I, Ozturk K, Esassolak M. Patterns of failure for early-stage glottic carcinoma: 10 years' experience in conformal radiotherapy era. J Cancer Res Ther 2019; 15 (03) 576-581
• 21 Ermiş E, Teo M, Dyker KE, Fosker C, Sen M, Prestwich RJ. Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions. Radiat Oncol 2015; 10: 203 Published 2015 Sep 23
• 22 Warde P, O'Sullivan B, Bristow RG. et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998; 41 (02) 347-353
• 23 Fowler JF, Harari PM, Leborgne F, Leborgne JH. Acute radiation reactions in oral and pharyngeal mucosa: tolerable levels in altered fractionation schedules. Radiother Oncol 2003; 69 (02) 161-168
• 24 Meade S, Sanghera P, McConkey C. et al. Revising the radiobiological model of synchronous chemotherapy in head-and-neck cancer: a new analysis examining reduced weighting of accelerated repopulation. Int J Radiat Oncol Biol Phys 2013; 86 (01) 157-163
• 25 Hartley A, Sanghera P, Kazi W. et al. Correlation of currently used radiobiological parameters with local control and acute and late mucosal toxicity in randomised studies of altered fractionation for locally advanced head and neck cancer. Clin Oncol (R Coll Radiol) 2011; 23 (01) 29-33
• 26 Sanghera P, McConkey C, Ho KF, Glaholm J, Hartley A. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2007; 67 (05) 1342-1351
• 27 Cetinayak O, Dogan E, Kuru A. et al. Outcome of Early-Stage Glottic Laryngeal Carcinoma Patients Treated with Radical Radiotherapy Using Different Techniques. J Oncol 2019; 2019: 8640549
• 28 https://www.rcr.ac.uk/system/files/publication/field_publication_files/bfco193_radiotherapy_dose_fractionation_third-edition-head-and-neck_0.pdf (date accessed 18.02.2020)
• 29 The National Comprehensive Cancer Network (NCCN) guidelines on head and neck cancers version 1.2021–Novermber 9, 2020.
• 30 Jung EK, Jin SM, Kim JG. et al. Comparison of long-term treatment outcomes of T2N0M0 laryngeal squamous cell carcinoma using different treatment methods. Oncol Lett 2020; 20 (01) 921-930